ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,789.70
0.52%
S&P ASX All Technology
3,450.00
0.25%
Brent Oil
70.285
0.00%
US Dollar vs AUD
1.5808
0.00%
Bitcoin
84,210.95
0.30%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Zymeworks Inc (ZYME) Share Price

Zymeworks Inc

Zymeworks Inc (ZYME)

NASDAQ
12.25
-0.30
(-2.39%)
Closed 15 March 7:00AM
Delayed by 15 minutes
12.19
-0.06
(-0.49%)
After Hours: 10:56AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
12.19
Bid
11.60
Offer
13.30
Volume
577,775
12.23 Day's Range 13.17
7.97 52 Week Range 17.70
Market Cap
839.617M
Previous Close
12.55
Open
12.955
Last Trade
4
@
12.86
Last Trade Time
Financial Volume
US$ 7,307,675
VWAP
12.648
Average Volume (3m)
524,362
Shares Outstanding
68,877,526
Dividend Yield
-
PE Ratio
-7.10
Earnings Per Share (EPS)
-1.72
Revenue
76.01M
Net Profit
-118.67M

About Zymeworks Inc

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiat... Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.zymeworks.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Zymeworks Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZYME. The last closing price for Zymeworks was US$12.55. Over the last year, Zymeworks shares have traded in a share price range of US$ 7.97 to US$ 17.70.

Zymeworks currently has 68,877,526 shares in issue. The market capitalisation of Zymeworks is US$864.41 million. Zymeworks has a price to earnings ratio (PE ratio) of -7.10.

Ask ADVFN Intelligence (AI)

ZYME Latest News

More News

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
06 March 2025
ZYME (-2.39%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
06 March 2025
ZYME (-2.39%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
06 March 2025
ZYME (-2.39%)

Form 8-K - Current report
Edgar (US Regulatory)
06 March 2025
ZYME (-2.39%)

Form 8-K - Current report
Edgar (US Regulatory)
18 February 2025
ZYME (-2.39%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.02-0.163800163812.2112.5710.96101520811.9236363CS
4-2.54-17.243720298714.7315.2510.9666692512.75941651CS
12-1.05-7.9305135951713.2417.0710.9652436213.60796399CS
26-0.41-3.2539682539712.617.710.9652711113.68684896CS
521.4613.606710158410.7317.77.9759884711.49672835CS
1565.8191.0658307216.3817.76.0156109489.91439879CS
2605.8191.0658307216.3817.76.0156109489.91439879CS

ZYME - Frequently Asked Questions (FAQ)

What is the current Zymeworks share price?
The current share price of Zymeworks is US$ 12.19
How many Zymeworks shares are in issue?
Zymeworks has 68,877,526 shares in issue
What is the market cap of Zymeworks?
The market capitalisation of Zymeworks is USD 864.41M
What is the 1 year trading range for Zymeworks share price?
Zymeworks has traded in the range of US$ 7.97 to US$ 17.70 during the past year
What is the PE ratio of Zymeworks?
The price to earnings ratio of Zymeworks is -7.1
What is the cash to sales ratio of Zymeworks?
The cash to sales ratio of Zymeworks is 11.09
What is the reporting currency for Zymeworks?
Zymeworks reports financial results in USD
What is the latest annual turnover for Zymeworks?
The latest annual turnover of Zymeworks is USD 76.01M
What is the latest annual profit for Zymeworks?
The latest annual profit of Zymeworks is USD -118.67M
What is the registered address of Zymeworks?
The registered address for Zymeworks is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Zymeworks website address?
The website address for Zymeworks is www.zymeworks.com
Which industry sector does Zymeworks operate in?
Zymeworks operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RDUSRadius Recycling Inc
US$ 27.902
(104.26%)
8.53M
BONBon Natural Life Ltd
US$ 1.40
(90.29%)
84M
SUNESUNation Energy Inc
US$ 0.5213
(62.96%)
513.96M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 255.00
(39.80%)
222
AAOIApplied Optoelectronics Inc
US$ 22.105
(39.29%)
17.01M
GLSTUGlobal Star Acquisition Inc
US$ 2.00
(-69.23%)
421
CURRCurrenc Group Inc
US$ 2.03
(-41.33%)
1.42M
ADTXAditxt Inc
US$ 0.0201
(-39.82%)
240.2M
HEPAHepion Pharmaceuticals Inc
US$ 0.0228
(-39.68%)
161.52M
WKSPWorksport Ltd
US$ 0.36205
(-35.45%)
4.96M
SUNESUNation Energy Inc
US$ 0.5213
(62.96%)
513.96M
NVDANVIDIA Corporation
US$ 121.67
(5.27%)
277.56M
ADTXAditxt Inc
US$ 0.0201
(-39.82%)
240.2M
HEPAHepion Pharmaceuticals Inc
US$ 0.0228
(-39.68%)
161.52M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 9.225
(7.64%)
160.21M

Discussion

View Full Feed
StockItOut StockItOut 4 minutes ago
Are you for real, dude? 'Cause that was funny!

I'm still thinking you're a bot.
XERI
joyceschoice joyceschoice 11 minutes ago
https://www.youtube.com/watch?v=Mv4lZwM3aZM
Jimmy Joe Jimmy Joe 16 minutes ago
https://www.youtube.com/watch?v=AP0TwQfe1BA
AMC
Investor2014 Investor2014 17 minutes ago
Also each national granted patent attracts annual maintenance fees to keep them enforceable!

So much BS posted here with ignorant confidence by folks who just claim to know stuff!
AVXL
fink fink 17 minutes ago
The annual says it has 95 shareholders?
Where did they come from. 712 shares a piece average.

Hard to believe the numbers.

Fannie Mae is getting my attention this week end. I think Trump is going to make it great Agsin
BUSC
XMaster2023 XMaster2023 18 minutes ago
You keep fishing for lawsuits from disgruntled investors when your boss is my only complaint. Soon Depositions will commence and we will see who has the last laugh.
NWBO
johnydollar johnydollar 28 minutes ago
There is this part i like most about whats about to go down........

The Trump administration, meanwhile, said halting FINRA's proceeding would "frustrate the political branches' (and the public's) goal of encouraging self-regulation of the securities industry," and the "strong congres
DBMM
joyceschoice joyceschoice 29 minutes ago
It did. None of my buy orders executed on TNA . My UVXY sell did print so next week we'll see.
TNA UVXY
redspeed redspeed 31 minutes ago
The Aeroplane deal that SteveC and many 'touted' here that was going to save the OTC...

Oh boi did Frank 2 get in on that,

Well another company did the deal and their market cap is now 1.5M.

At least they have assets.

This was the deal the
MONI
Jaguarjacket Jaguarjacket 32 minutes ago
"We're committed to innovation, accessibility, and sustainable growth for our stakeholders."
ADIA
janice shell janice shell 32 minutes ago
I can't imagine why they'd vote for Tommy Tubby. And yet they did.
newmedman newmedman 34 minutes ago
I wouldn't go that far. He wasn't the sharpest tool in the shed, he just knew how to assert himself into any process. I'm sure most people around here wouldn't vote for him if he's still alive.
Jaguarjacket Jaguarjacket 34 minutes ago
The share retirement effort further solidifies corporate governance, amplifying investor confidence, as ADIA Nutrition strengthens its position as a leader in regenerative medicine innovation.
ADIA
jeddiemack jeddiemack 34 minutes ago
Kudos
FNMA
littlejohn littlejohn 35 minutes ago
Friday market move was inverted to consumer sentiment

and inflation expectation news out...

https://www.barchart.com/story/news/31410537/stocks-recover-some-of-this-weeks-losses-as-us-shutdown-seems-averted

Stocks fell back from their best levels after to
Jaguarjacket Jaguarjacket 36 minutes ago
The OTCQB uplisting process, now in clear sight with the shell risk designation lifted
ADIA
janice shell janice shell 36 minutes ago
Repealing the 19th amendment, what a great idea.

Do we really want people who vote based upon emotion?

Men are far more emotional than women, Bolshie.
Jaguarjacket Jaguarjacket 38 minutes ago
"This is just the start."
ADIA
benz280c benz280c 39 minutes ago
FungyDirt and Idesell probably panic-bought during all the excitement 🤣🤣🤣

Hahahaha
GDVM
Jaguarjacket Jaguarjacket 39 minutes ago
These February triumphs build on January's success, when the Adia Med Winter Park Clinic exceeded financial expectations in its first operational month, covering all opening expenses with surplus revenue
ADIA
jeddiemack jeddiemack 40 minutes ago
The net worth swipe and the ultimate and continuing liquidation preference is harmful to the owners of the entities. The problem is... this is a continuing crime. its like they are tapped into the blood of the beast and sucking it dry... vampires!
FNMA
Investor082 Investor082 40 minutes ago
I agree with you. The data is good enough to be approved in UK after scrutiny (given the trial design) because of their connections and network there but not game changing where regulators will prioritize and make exceptions. No wonder LP didn't apply for reimbursement last year because she knows NI
NWBO

Your Recent History

NASDAQ
ZYME
Zymeworks
NASDAQ
TCBP
TC BioPharm
LSE
0LY9
Fabryka Obrabiarek Rafamet
DOWI
DJIETLS
DJ Islamic Market World ...
LSE
53CV
Gen.elec 3.75%
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads